The healthtech sector weathered significant challenges in Q1, with most public companies experiencing share price declines mirroring broader market losses. The virtual care and remote patient monitoring segment was particularly hard hit, although benefit management companies such as Claritev and Progyny bucked the trend with gains of 58% and 26%, respectively. The Trump administration’s tariff announcements have created market volatility, potentially delaying anticipated IPOs such as Hinge Health and further straining the sector’s already limited liquidity options. Q1 also saw major structural changes with two significant take-private transactions.
Read the full article: PitchBook Q1 2025 Healthtech Public Comp Sheet and Valuation Guide //
Source: https://pitchbook.com/news/reports/q1-2025-healthtech-public-comp-sheet-and-valuation-guide